Get access

Efficacy of icatibant treatment in patients with hereditary angio-oedema type I resistant to treatment with C1 inhibitor concentrate


  • Funding sources: No specific grant or funding was associated with this study. Financial support for development of this manuscript was provided by Shire Human Genetic Therapies, Inc.

  • Conflicts of interest: L.B. and I.B.-G. have received consultancy fees from CSL Behring and Shire Human Genetic Therapies, Inc.

  • Data from this report were presented at the 18th Congress of the European Academy of Dermatology and Venereology, Berlin, Germany, 7–11 October 2009.

No abstract is available for this article.